The ACCELERATE Trial
Nicholls_ACCELERATE
Nicholls_ACCELERATE
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
Secondary Efficacy Endpoints<br />
Placebo<br />
(n=6054)<br />
Evacetrapib<br />
(n=6038)<br />
CV death, MI, stroke 444 (7.3) 434 (7.2)<br />
CV death 163 (2.7) 140 (2.3)<br />
MI 255 (4.2) 256 (4.2)<br />
Stroke 95 (1.6) 92 (1.5)<br />
Hospitalization for unstable<br />
angina<br />
143 (2.4) 155 (2.6)<br />
Coronary revascularization 482 (8.0%) 485 (8.0%)<br />
All cause mortality 269 (4.4) 227 (3.8)<br />
HR<br />
(95% CI)<br />
0.98<br />
(0.86,1.12)<br />
0.86<br />
(0.68,1.08)<br />
1.00<br />
(0.84,1.19)<br />
0.97<br />
(0.73,1.29)<br />
1.08<br />
(0.86,1.36)<br />
1.01<br />
(0.89, 1.14)<br />
0.84<br />
(0.71-1.01)<br />
P<br />
Value<br />
0.73<br />
0.18<br />
0.97<br />
0.82<br />
0.48<br />
0.92<br />
0.06<br />
Preliminary analysis prior to formal database lock
Change language